Recent advances in infertility treatment
Reading File
Finding Sources
Finding Sources
Searching PubMed
"infertility" AND "treatment"
Searching the Web
recent advances infertility treatment 2024 2025 IVF ART
Reading File
Finding Sources
Searching PubMed
"IVF" AND "artificial intelligence" AND "embryo selection"
Reading Web Page
recent advances infertility treatment IVF ART 2024 2025
Reading File
Finding Sources
Finding Sources
Searching PubMed
"preimplantation genetic testing" AND "aneuploidy" AND "IVF outcomes"
Reading File
Finding Sources
Finding Sources
Searching PubMed
"diminished ovarian reserve" AND "treatment" AND "fertility"
Reading File
Finding Sources
Searching PubMed
"platelet rich plasma" AND "ovarian" AND "infertility"
Reading File
Reading File
Searching PubMed
"endometrial receptivity" AND "implantation" AND "IVF"
I now have comprehensive material to compose a thorough, well-cited answer. Let me synthesize everything.
Recent Advances in Infertility Treatment
Infertility — defined as failure to conceive after 12 months of unprotected intercourse — affects approximately 10–15% of couples worldwide. The field has undergone rapid evolution across several fronts:
1. Assisted Reproductive Technology (ART): IVF and Beyond
The fundamental ART protocol remains: controlled ovarian stimulation → oocyte retrieval → fertilization → embryo culture → transfer. But each step has advanced substantially.
IVF as first-line therapy: Multiple trials (FASTT trial, FORT-T trial) now support IVF as first-line treatment for unexplained infertility over older stepwise approaches like clomiphene/IUI or FSH/IUI. Per-cycle ongoing pregnancy rates are approximately 30.7% for IVF versus 7.6% (CC/IUI) and 9.8% (FSH/IUI). For women aged 38–42, IVF similarly outperforms ovulation induction/IUI for live birth rates. — Berek & Novak's Gynecology, p. 2072
GnRH antagonist protocols: Antagonist-based controlled ovarian stimulation has largely replaced long agonist protocols. Antagonists are associated with shorter stimulation duration, lower FSH doses, and significantly reduced rates of ovarian hyperstimulation syndrome (OHSS), which remains the major ART complication. — Berek & Novak's Gynecology
Vitrification (ultra-rapid cryopreservation): Replaced slow-freeze protocols; oocyte and embryo survival rates post-thaw now approach fresh-cycle outcomes, enabling elective frozen embryo transfer (eFET) strategies. This also underpins fertility preservation for oncology patients and egg banking.
2. Preimplantation Genetic Testing (PGT) — New Generation
PGT has evolved from FISH-based blastomere biopsy (version 1.0, which paradoxically decreased pregnancy rates in some RCTs) to a sophisticated trophectoderm biopsy platform:
- PGT-A (aneuploidy): Blastocyst-stage trophectoderm biopsy (day 5/6) + whole-genome analysis by next-generation sequencing (NGS/massive parallel sequencing) or array CGH, followed by single frozen-euploid embryo transfer. This approach reduces embryo chromosomal error, particularly relevant since >30% of embryos in women over 35, and up to 60% in women over 40, are aneuploid. — Creasy & Resnik's Maternal-Fetal Medicine
- PGT-M (monogenic): Testing for specific heritable disorders
- PGT-SR (structural rearrangements): Detection of unbalanced chromosomal translocations
- Non-invasive PGT (niPGT): An emerging frontier using cell-free DNA from spent blastocyst culture medium to infer embryo chromosome status — avoiding the embryo biopsy entirely. A 2024 preprint (Peking University/Yikon Genomics collaboration) reported 100% accuracy for niPGT-M for monogenic diseases using improved Bayesian modeling. Standardization and validation remain ongoing.
A 2024 systematic review (Taskin et al., PMID 38973269) confirmed that comprehensive chromosome screening via PGT-A with NGS improves implantation outcomes, with ongoing refinements regarding mosaic embryo management.
3. Intracytoplasmic Sperm Injection (ICSI) and Male Factor Infertility
ICSI transformed severe male-factor infertility by reducing the sperm requirement from hundreds of thousands (conventional IVF) to a single viable sperm. — Smith & Tanagho's General Urology, p. 744
Current advances include:
- Micro-TESE (microsurgical testicular sperm extraction): For non-obstructive azoospermia, allows retrieval of viable sperm from seminiferous tubules even when no sperm is present in ejaculate.
- Sperm DNA fragmentation testing + MACS (magnetic-activated cell sorting): Selects genetically intact sperm for ICSI, improving embryo quality. High DNA fragmentation is now recognized as an independent contributor to recurrent IVF failure.
- Surgical sperm sources: Includes vas deferens, epididymis (PESA/MESA), and testis (TESA/micro-TESE), enabling biologic parenthood even in obstructive or non-obstructive azoospermia. — Harrison's Principles of Internal Medicine 22E, 2025
Treatment algorithm for male factor (per Harrison's 2025):
- Mild (15–20 ×10⁶/mL, normal motility): Expectant management
- Moderate (10–15 ×10⁶/mL, 20–40% motility): IUI ± ovulation induction, may need IVF ± ICSI
- Severe (<10 ×10⁶/mL, <10% motility): IVF + ICSI or donor sperm
4. Artificial Intelligence in Embryo Selection
AI and deep learning applied to time-lapse embryo imaging represent one of the most active frontiers. Algorithms analyze morphokinetic parameters (timing of cell divisions, multinucleation events, blastulation dynamics) to rank embryo viability, potentially matching or surpassing embryologist judgment for selection.
A 2025 scoping review (AlSaad et al., PMID 40264925, Front Reprod Health) identified deep learning models achieving high accuracy for embryo assessment using time-lapse imaging systems. Platforms like Vitrolife's KIDScore and similar tools are entering clinical deployment. The challenge is prospective validation in sufficiently powered RCTs — current evidence shows promise but standardization across labs and datasets is lacking.
5. Diminished Ovarian Reserve (DOR): Emerging Therapies
DOR — characterized by low AFC, low AMH, and poor ovarian response — has historically offered limited options. Several novel approaches are showing early evidence:
Platelet-Rich Plasma (PRP) intraovarian injection: A 2024 systematic review and meta-analysis (Éliás et al., PMID 38760869, J Ovarian Res) found that ovarian PRP significantly improved AMH levels, AFC, and reproductive outcomes (clinical pregnancy and live birth rates) in DOR patients across 14 studies. The mechanism is hypothesized to involve growth factors (PDGF, VEGF, IGF-1) promoting follicular recruitment and angiogenesis. This remains investigational but is gaining clinical traction.
Nutritional/antioxidant adjuncts: A 2024 meta-analysis (Shang et al., PMID 39019217, Advances in Nutrition) reviewed antioxidants (CoQ10, DHEA, melatonin, vitamin D) in women with ovarian aging, finding evidence for improved ovarian reserve markers. A 2025 meta-analysis (Li et al., PMID 41185971, Annals of Medicine) confirmed oral nutritional supplements (CoQ10, resveratrol, DHEA) modestly improve IVF parameters in DOR women.
Comprehensive management review: Conforti et al. (PMID 39332623, Fertility & Sterility, 2025) systematically reviewed RCTs for DOR management, finding that evidence-based interventions remain limited but include individualized stimulation protocols (mild/natural cycle IVF, low-dose FSH) and adjuncts like growth hormone co-treatment.
6. Tubal Factor Infertility: Surgery vs. ART
As IVF success rates improve, indications for surgical tuboplasty have narrowed:
- Proximal occlusion: Tubal catheterization/cannulation restores patency in up to 85%, with ongoing pregnancy rates of 12–44%. If occlusion recurs, IVF is recommended.
- Distal occlusion: Fimbrioplasty (pregnancy rates 55–60% in well-selected patients) and salpingostomy remain options for young patients (<35) with mild disease and normal mucosa; older patients or those with severe disease should proceed to IVF.
- Hydrosalpinx: Salpingectomy before IVF improves live birth rates by 2-fold (by eliminating the toxic embryotoxic fluid reflux). — Berek & Novak's Gynecology, pp. 2060–2061
7. Endometrial Receptivity and Implantation Research
Implantation failure accounts for a large proportion of IVF failures despite euploid embryos. Advances in this area include:
- Endometrial Receptivity Array (ERA): Transcriptomic profiling to identify the "window of implantation" — though a 2024 systematic meta-analysis (Bulletti et al., PMID 40028443) found mixed evidence for ERA improving live birth in unselected populations; benefit is likely confined to patients with recurrent implantation failure.
- Uterine microbiome: Dominance of Lactobacillus species in the endometrial microbiome correlates with better IVF outcomes; dysbiosis (especially non-Lactobacillus-dominant flora) is associated with implantation failure. Testing and microbiome-targeted interventions are entering clinical trials.
- Epigenetic regulation: HOXA10/HOXA11 methylation has been identified as an epigenetic barrier to receptivity (Kudlay et al., PMID 41153447, 2025).
- Endometrial biotechnologies: A 2024 systematic review (Rodríguez-Eguren et al., PMID 38796750, Human Reproduction Update) catalogued regenerative therapies for endometrial disorders including platelet-rich plasma intrauterine infusion, stem cell therapies, and bioengineered scaffolds for Asherman syndrome — all showing early-phase promise.
8. Fertility Preservation
Oncofertility has become standard of care: oocyte vitrification before gonadotoxic chemotherapy or radiotherapy is now recommended for pre-menopausal women. Ovarian tissue cryopreservation and transplantation has yielded >200 live births globally and is emerging from experimental status. Testicular tissue cryopreservation for prepubertal boys remains investigational.
Summary Table
| Domain | Key Advance | Evidence Level |
|---|---|---|
| IVF protocol | GnRH antagonist; eFET strategy | RCTs |
| Embryo genetics | NGS-based PGT-A at blastocyst stage | Meta-analyses |
| Non-invasive PGT | cfDNA from spent culture medium (niPGT) | Investigational |
| Male infertility | Micro-TESE, MACS, sperm DNA fragmentation | Observational/SR |
| AI in ART | Deep learning for embryo morphokinetics | Scoping review (2025) |
| Diminished ovarian reserve | Intraovarian PRP, CoQ10/DHEA | Meta-analyses (2024–25) |
| Endometrium | ERA, microbiome testing, regenerative therapies | Early-phase RCTs |
| Fertility preservation | Oocyte vitrification; ovarian tissue transplantation | Established/Emerging |
Key recent literature:
- Éliás et al. Intraovarian PRP for DOR. J Ovarian Res 2024 — PMID 38760869
- AlSaad et al. Deep learning for embryo assessment. Front Reprod Health 2025 — PMID 40264925
- Conforti et al. DOR management RCT review. Fertil Steril 2025 — PMID 39332623
- Bulletti et al. Implantation failure. Front Endocrinol 2024 — PMID 40028443
- Rodríguez-Eguren et al. Endometrial biotechnologies. Hum Reprod Update 2024 — PMID 38796750
- Taskin et al. PGT-A meta-analysis. Int J Fertil Steril 2024 — PMID 38973269
This is a shared conversation. Sign in to Orris to start your own chat.